Redwood AI Banks on Post-Quantum Security with All-Share Deal, but Market Punishes Dilution Risk

Redwood AI is chasing two new growth horizons in the same week – artificial intelligence-driven drug discovery and quantum-era cybersecurity – but the currency it plans to use for the latter acquisition has sent shares sliding on both sides of the border.

The Vancouver-based company signed a non-binding letter of intent on May 28 to buy Quantum.IQ, a fellow Canadian outfit that builds AI-powered platforms for post-quantum cryptography. The target’s software helps government agencies, defence contractors, critical infrastructure operators and financial institutions detect cryptographic vulnerabilities, map out compliance roadmaps and monitor for emerging quantum threats. For Redwood, whose existing business revolves around AI software for chemistry and pharma applications, the deal would mark a sharp pivot into the security market.

Investors, however, focused on the price tag: up to 14 million newly issued Redwood common shares. Half of those – 7 million – are due at closing, and the remaining 7 million depend on hitting unspecified performance milestones. The stock will be released gradually under a 24-month escrow schedule: 10% after four months, 15% after six, 25% after twelve, another 25% after eighteen, and the final 25% after two years.

The market reaction was swift and severe. On the OTCQB in the United States, Redwood shares plunged 46.03% on Friday, May 29, to $1.70 from a prior close of $3.15. On the Canadian Securities Exchange, the stock lost 18% that same day to close at CAD 3.70, bringing its five-day decline to more than 53%. European trading also saw wild swings, with the stock briefly touching €3.765 before retreating; it now sits roughly 44% below the April high of €6.66.

Should investors sell immediately? Or is it worth buying Redwood AI?

The all-stock structure of the proposed takeover – with no cash component – left traders bracing for heavy dilution just as Redwood’s outstanding share count was already expanding. The deal remains tentative, subject to due diligence, final contracts and approval from the Canadian Securities Exchange. Redwood itself flagged a list of risks including missing regulatory green lights, dependence on key personnel and the early-stage nature of quantum technology.

Alongside the acquisition news, Redwood reported several other operational developments that initially failed to calm investor nerves. On May 26, the company secured DTC eligibility for its shares, enabling faster electronic clearing and settlement on the OTCQB. Its subsidiary Redwood AI Operations Inc. won a grant of up to CAD 240,000 for its Q-SAFE initiative, which aims to develop quantum-safe security frameworks. Additionally, the company signed an investor relations agreement with IBN valued at roughly $114,000.

Just days earlier, on May 22, Redwood had announced a partnership with Resilience Biosciences to build AI-driven workflows for small-molecule drug development, focusing on computational chemistry and synthetic route planning. That collaboration – combined with the Quantum.IQ pursuit – gives Redwood two new thematic arrows in its quiver within a single week: quantum security and AI-powered pharma R&D.

Redwood AI at a turning point? This analysis reveals what investors need to know now.

Whether the Quantum.IQ takeover progresses to a binding agreement will be decided over the coming weeks of due diligence. Until then, the overhang of potential stock issuance remains the central force weighing on the equity – and the biggest test of investor trust in management’s strategic vision.

Ad

Redwood AI Stock: New Analysis - 30 May

Fresh Redwood AI information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Redwood AI analysis...

en | CA7579221093 | REDWOOD | boerse | 69448832 |